Dexmedetomidine: A new option for intractable distress in the dying [4]

Journal of Pain and Symptom Management

Volumn 24, Issue 1, 2002, Pages 6-8

  Soares, Luiz Guilherme L ^a   Naylor, Cláudia ^a   Martins, Maurílio A ^a   Peixoto, Geralda ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DEXMEDETOMIDINE; FENTANYL; FUROSEMIDE; HALOPERIDOL; MIDAZOLAM; MORPHINE;

ADULT; BREAST CANCER; CANCER PAIN; CANCER PALLIATIVE THERAPY; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISTRESS SYNDROME; DYING; FEMALE; HUMAN; LETTER; MALE; METASTASIS; PARAGANGLIOMA; PROGNOSIS; SEDATION; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

ADRENERGIC ALPHA-AGONISTS; ADULT; DEXMEDETOMIDINE; FATAL OUTCOME; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; NEOPLASMS; PAIN, INTRACTABLE; PALLIATIVE CARE;

EID: 0036050029     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(02)00423-2     Document Type: Letter

References (10)

1. Sedation for intractable distress in the dying. A survey of experts
2. Clinical uses of alpha-2 adrenergic agonists
3. Sedation in the imminently dying patient
4. Symptom prevalence and control during cancer patient's last days of life
5. Sedation for symptom control in Japan: The importance of intermittent use and communication with family members
6. Effects of high doses opioids and sedatives on survival in terminally ill
7. Temporary sedation with midazolam for control of severe incident pain
8. Dexmedetomidine
9. Dexmedetomidine, a novel alpha-2 adrenergic agonist. A review of its pharmacodynamic characteristics
10. Sedative, amnesic, and analgesic properties of small-dose dexmedetomidine infusions